Toronto, ON – December 4th, 2025 – With rapidly increasing demand for medical isotopes, Canada will need to strengthen its domestic production capacity to maintain continuous patient access to life-saving diagnostic scans and a growing new category of novel, life-extending radiotherapeutics. With this context, the Canadian Nuclear Isotope Council (CNIC) is proud to welcome its newest member organization, Cross River Infrastructure Partners, which plays a key role in developing the infrastructure required to support a stable and resilient isotope supply chain in Canada.
Medical isotopes, such as Technetium-99m (Tc-99m) and its precursor Molybdenum-99 (Mo-99) used in SPECT diagnostic imaging, and Lutetium-177 (Lu-177) used for targeted cancer treatments, are foundational to modern healthcare and play an increasing role in treating the most life-threatening diseases like cancer. Ensuring reliable access requires planning, new production capacity, and coordinated cross-border integrated infrastructure investments that match the growing needs of patients and clinicians.
Within Canada’s ecosystem, Cross River Infrastructure Partners is developing projects that directly support this expanded capacity. In collaboration with Eden Radioisotopes, the organizations are advancing a dedicated medical isotope reactor and integrated hot cell processing facility in New Brunswick, designed to enable fully resilient, (n-1) concurrent and continuous production of Mo-99 (high specific activity), Lu-177, and additional therapeutic isotopes as clinical use evolves. This new reactor and processing facility could provide priority access to life-saving medical isotopes for patients across Atlantic Canada.
“Sustainable isotope access depends on strong infrastructure and a reliable supply chain”, said Melody Greaves, Executive Director & VP, Government Relations at the CNIC. “Cross River Infrastructure Partners’ work supports the development of new production capacity that will strengthen our national capabilities, while complementing Canada’s existing fleet of reactors, cyclotrons, and isotope production facilities.”
“Isotope shortages have real human consequences,” said Andrew Wilder, CEO at Cross River Infrastructure Partners. “Alongside Eden Radioisotopes, we are advancing a complementary New Mexico–New Brunswick model that adds (n-1) resiliency and geo-political diversification for delivery across Canada, the Northeast U.S., Europe, and global markets. Coupling New Brunswick’s strategic geography and nuclear familiarity with Eden’s emerging low-cost advantage strengthens both domestic security and international patient access.”
Cross River’s capabilities in coordinating large-scale, nuclear infrastructure development brings critical value to the CNIC membership as Canada strengthens its leadership in isotope production.
To learn more about Cross River Infrastructure Partners, visit www.crossriverllc.com; and for Eden Radioisotopes, visit www.edenrad.com.
About the Canadian Nuclear Isotope Council
The Canadian Nuclear Isotope Council (CNIC) is an independent, not-for-profit advocacy and member services organization. The CNIC supports over 115 members from across science, academia, healthcare, and nuclear-sector organizations dedicated to maintaining Canada’s position as a global leader in the production of life-saving isotopes. The CNIC raises awareness and advocates for long-term policies that support health-care innovation and will save countless lives for decades to come.
To learn more about the CNIC, visit www.CanadianIsotopes.ca and follow us on Facebook, Twitter, and LinkedIn, or please contact:
Evan Cameron
Manager, Public Affairs and Communications
Canadian Nuclear Isotope Council
evan.cameron@canadianisotopes.ca